Search PubMed⌕ Search

Biomedical subjects

N Sugaya

Publications and source records attributed to N Sugaya.

At least 55 records · Page 3Linked to original sources
PubMed1987

Increased lactate dehydrogenase in serum in measles infection.

We determined lactate dehydrogenase (LD; EC 1.1.1.27) in serum from 75 sequential measles patients and 105 control patients. In the measles patients, LD was increased to 1147.9 +/- 43.8 (mean +/- SE) U/L, markedly more than in the control group (517.2 +/- 15.0 U/L, p less than 0.001). Both LD-3 and LD-4 isoenzymes were increased, but the concentration of LD-5 was normal. Patients with high LD values (greater than 1500 U/L) had longer hospital stays than did those with lower values (p less than 0.01). Our results suggest that increased LD in serum is a common finding in measles infection and presumably originates from lymphocytes.

Bronchitis↗
PubMed1984

[Clinical studies of sulbactam/cefoperazone therapy in pediatric bacterial infections].

Sulbactam/cefoperazone (SBT/CPZ) was administered intravenously to 9 patients with respiratory infections (H. influenzae 6 cases, pathogens unknown 3 cases), 2 patients with urinary tract infection (E. coli and C. freundii; both cases had VUR), and 1 patient with staphylococcal bacteremia. In these causative bacteria, 5 strains (H. influenzae 3, E. coli 1 and S. aureus 1) were beta-lactamase producers. Bacteriological efficacy (eradication rate) was complete (9/9, 100%) and clinical efficacy was also complete (12/12, 100%). In comparison with CPZ alone, MICs of SBT/CPZ against beta-lactamase producing bacteria were superior. Although mild side effect was observed in 1 case (eosinophilia), no other severe form of adverse reaction were encountered. It was concluded that SBT/CPZ was an useful antibiotic for the treatment of pediatric bacterial infections, especially caused by beta-lactamase (penicillinase) producing bacteria.

Age Factors↗
PubMed1984

[Fundamental and clinical studies of ceftazidime in the field of pediatrics].

We have studied ceftazidime (CAZ), a cephem antibiotic of the new generation, for its antibacterial activity against H. influenzae and clinical effects. Antibacterial activity: MICs of CAZ for 142 strains of H. influenzae including 11 ABPC-resistant strains which were clinically isolated, were determined, and the results were good for all the strains. Clinical effects: CAZ was administered to 9 children with infections. Suspected causative organisms were H. influenzae, E. coli, P. aeruginosa, group B Streptococcus and S. pneumoniae. Eradication of these organisms was confirmed in all the strains except for one in which the antibacterial effect of CAZ was unknown. Clinical efficacy was excellent or good in all the cases. No side effect was observed except for eosinophilia noted in 1 case.

Adolescent↗
PubMed1983

[Clinical investigation of combined therapy (cefotiam, sulbenicillin and cefsulodin) against infections complicated by acute leukemia].

Prophylaxis effect and clinical therapy of combination use of cefotiam (CTM), sulbenicillin (SBPC) and cefsulodin (CFS) have been investigated, and the results were as follows. 1. Prophylaxis effect of CTM-SBPC combination therapy was very useful. CTM-SBPC combination therapy was performed to patients who are at high risk for infectious complications. Prophylaxis effect of CTM-SBPC was judged by fever over 38 degrees C, and was better than usual antibiotic treatment. 2. CTM-SPBC-CFS combination therapy was performed against severe infections during early remission, and the overall effectiveness rate was 83.3% (5/6). 3. No remarkable side effect was observed in this investigation.

Acute Disease↗